Premium
CYPROTERONE ACETATE, AN ALTERNATIVE GESTAGEN IN POSTMENOPAUSAL OESTROGEN/GESTAGEN THERAPY
Author(s) -
RIIS B. J.,
JENSEN J.,
CHRISTIANSEN C.
Publication year - 1987
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1987.tb00790.x
Subject(s) - cyproterone acetate , endocrinology , medicine , estradiol valerate , placebo , bone mineral , cyproterone , bone remodeling , valerate , chlormadinone acetate , parathyroid hormone , osteoporosis , calcium , hormone , chemistry , androgen , population , biochemistry , health services , butyrate , alternative medicine , environmental health , pathology , fermentation
SUMMARY Seventy‐six healthy, early postmenopausal women (aged 45–54 years) were allocated to 2 years of treatment with a cyclic combination of 2 mg oestradiol valerate (21 d) and 1 mg cyproterone acetate (11 d) or placebo. Sixty‐five women (86%) completed the study. In the placebo group the bone mineral content in the forearms (measured by single photon absorptiometry) and the bone mineral content in the lumbar spine and total skeleton (measured by dual photon absorptiometry) decreased significantly and at the same magnitude ( P < 0001), whereas all bone mass measurements remained unchanged in the hormone‐treated group. In the hormone‐treated group there was a significant decrease in biochemical estimates of bone turnover (serum alkaline phosphatase, serum phosphate, fasting urinary calcium and hydroxyproline), whereas these values were unchanged in the placebo treated group. We conclude that treatment with a cyclic combination of 2 mg oestradiol valerate and 1 mg cyproterone acetate is effective as prophylaxis of postmenopausal bone loss.